SYPRIS SOLUTIONS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SYPRIS SOLUTIONS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $82.29M | Mar 20, 2018 |
| FY2017 | Dec 31, 2016 | $91.80M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $145.32M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $354.78M | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | $73.86M | Mar 11, 2014 |
| FY2013 | Sep 30, 2013 | $76.28M | Mar 11, 2014 |
| FY2013 | Jun 30, 2013 | $82.17M | Mar 11, 2014 |
| FY2013 | Mar 31, 2013 | $78.41M | Mar 11, 2014 |
| FY2013 | Dec 31, 2012 | $67.47M | Mar 11, 2014 |
| FY2012 | Sep 30, 2012 | $78.76M | Mar 12, 2013 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $82.29M | Mar 20, 2018 |
| FY2017 | Dec 31, 2016 | $91.80M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $145.32M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $354.78M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $310.71M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $341.60M | Mar 11, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.40M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.89M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $17.25M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $14.85M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.51M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $12.05M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $9.88M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $7.57M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $3.33M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $749.0K | Mar 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.34M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.68M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.60M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($2.49M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.92M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.67M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($3.95M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($3.51M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($10.82M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $6.04M | Mar 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.61M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.93M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $969.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $364.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.91M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $90.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($4.31M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($4.30M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($12.15M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($22.76M) | Mar 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 28, 2019 |
| FY2018 | Dec 31, 2017 | $38.0K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $330.0K | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $779.0K | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $579.0K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $3.05M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $3.82M | Mar 11, 2014 |
| FY2012 | Dec 31, 2011 | $3.40M | Mar 12, 2013 |
| FY2011 | Dec 31, 2010 | $3.15M | Mar 13, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.00M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $16.96M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $16.28M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $14.49M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $12.60M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $11.96M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $13.68M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $10.47M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $13.08M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $22.01M | Mar 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.73M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.00M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($11.09M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.79M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.24M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.65M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($5.85M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.89M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($9.46M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($19.30M) | Mar 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $756.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.08M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.14M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.04M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.82M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.54M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $859.0K | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $2.05M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.64M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.76M | Mar 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.81M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $119.38M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $129.34M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $104.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $79.51M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $60.71M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $60.06M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $61.57M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $57.16M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $62.64M | Mar 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.02M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $99.80M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $106.88M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $84.57M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $60.22M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $45.93M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $46.63M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $46.73M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $40.23M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $36.54M | Mar 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.79M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.58M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.47M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $19.58M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $19.29M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $14.78M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $13.43M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $14.83M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $16.93M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $26.10M | Mar 20, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 11, 2014 |
| FY2012 | Dec 31, 2012 | $6.90M | Mar 12, 2013 |
| FY2011 | Dec 31, 2011 | $6.90M | Mar 13, 2012 |
| FY2011 | Dec 31, 2010 | $6.90M | Mar 13, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($124.95M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($118.61M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($116.93M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($115.34M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($112.84M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($115.77M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($117.43M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($114.93M) | Mar 19, 2020 |
| FY2018 | Jan 1, 2018 | ($111.42M) | Mar 28, 2019 |
| FY2018 | Dec 31, 2017 | ($111.59M) | Mar 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $5.10M | Mar 19, 2020 |
| FY2019 | Dec 31, 2018 | $10.70M | Mar 19, 2020 |
| FY2019 | Dec 31, 2017 | $8.14M | Mar 19, 2020 |
| FY2018 | Dec 31, 2016 | $16.77M | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | $1.35M | Mar 20, 2018 |
| FY2016 | Dec 31, 2014 | $7.00M | Mar 28, 2017 |
| FY2015 | Dec 31, 2013 | $18.67M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $18.66M | Mar 31, 2015 |
| FY2013 | Dec 31, 2011 | $18.17M | Mar 11, 2014 |
| FY2012 | Dec 31, 2010 | $16.59M | Mar 12, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $19.35M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $17.00M | Mar 30, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 21.30M | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | 21.30M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 21.40M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 21.42M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 21.33M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | 20.78M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | 20.49M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 20.40M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 20.16M | Mar 11, 2014 |
| FY2012 | Dec 31, 2011 | 20.00M | Mar 12, 2013 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $410.0K | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $1.64M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $1.22M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $1.61M | Mar 11, 2014 |